Roche revealed in its first-quarter results statement that giredestrant missed the mark in the phase 2 acelERA trial in advanced breast cancer, in what appears to be another blow to the emerging ...
Data from a phase 2 trial of Roche's oral BTK inhibitor fenebrutinib have shown "near-complete suppression" of disease activity and disability progression in relapsing multiple sclerosis (MS).
FRANKFURT, Jan 30 (Reuters) - Roche (ROG.S), opens new tab said on Thursday it is targeting a continued increase in adjusted earnings per share (EPS) at a high single-digit percentage this year ...
The latest Market Talks covering the Health Care sector. Published exclusively on Dow Jones Newswires at 4:20 ET, 12:20 ET and 16:50 ET. 0627 ET – Roche’s solid full-year results, which were broadly ...